CTLA4 and breast cancer: The authors demonstrated on several clinically relevant BC models, including orthotopic BCs (EO771, 4T1, and MCaP0008) and spontaneous BCs (MMTV-PyVT, which mirrors BC progression in humans), that CTLA4 and PD-1 antagonists increase blood perfusion of the tumor while they exert antitumor activities [123].